What is it about?
A multicentre study to show the various clinical, genetic and therapeutic characteristics of patients that are not controlled by the highest recommended dose of cabergoline (2 mg/week).
Featured Image
Why is it important?
These patients tend to be males, and a minority have AIP or MEN1 mutations; debulking surgery can provide improvements in later medical therapy in some cases.
Read the Original
This page is a summary of: Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients, August 2012, Bioscientifica,
DOI: 10.1530/EJE-12-0236.
You can read the full text:
Resources
Contributors
The following have contributed to this page
